Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
68,772.16 +1,123.08 (+1.66%) CMC Crypto 200
1,442.50 -25.60 (-1.74%)
Perspective Therapeutics, Inc. (AAJ.F)
| Previous close | 1.4500 |
| Open | 1.3800 |
| Bid | 0.0000 x 800000 |
| Ask | 0.0000 x 750000 |
| Day's range | 1.3500 - 1.3800 |
| 52-week range | 0.1990 - 1.7200 |
| Volume | |
| Avg. volume | 448 |
| Market cap | 840.549M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.97 |
GlobeNewswirePerspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock
- GlobeNewswire
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company’s sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging (“SNMMI”) Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 20
- GlobeNewswire
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
Continued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation protein-αAnnounced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sitesRaised $177.2 million in gross proceeds through various financing transactions and raised an additional $49.5 million subsequent to March 31st under our ATM Agreement. SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Persp
